OnKure Therapeutics Inc. (OKUR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

OnKure Therapeutics Inc. (OKUR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.40

-0.86 (-11.85%)

At close: Jan 14, 2025, 3:59 PM

6.38

-0.31%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.56
Market Cap	80.98M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.08
PE Ratio (ttm)	80
Forward PE	n/a
Analyst	Buy

Ask	7.33
Volume	238,522
Avg. Volume (20D)	103,137
Open	7.35
Previous Close	7.26
Day's Range	6.32 - 7.67
52-Week Range	6.32 - 20.00
Beta	undefined

About OKUR

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date n/a

Employees 50

Stock Exchange NASDAQ

Ticker Symbol OKUR

Website https://onkuretherapeutics.com

Analyst Forecast

According to 3 analyst ratings, the average rating for OKUR stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 446.88% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

News

2 months ago · seekingalpha.com

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond

Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...